Oncolytics Biotech Inc (TO:ONC) — Market Cap & Net Worth
Market Cap & Net Worth: Oncolytics Biotech Inc (ONC)
Oncolytics Biotech Inc (TO:ONC) has a market capitalization of $142.51 Million (CA$197.01 Million) as of September 19, 2026. Listed on the TO stock exchange, this Canada-based company holds position #17939 globally and #587 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncolytics Biotech Inc's stock price CA$14.90 by its total outstanding shares 100361000 (100.36 Million). Also see Oncolytics Biotech Inc assets under control for a full breakdown of the balance sheet.
Oncolytics Biotech Inc Market Cap History: 2015 to 2025
Oncolytics Biotech Inc's market capitalization history from 2015 to 2025. Data shows growth from $265.53 Million to $1.08 Billion (10.98% CAGR). Also see ONC cash generation efficiency for how efficiently the company converts equity into cash flow.
Oncolytics Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncolytics Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ONC stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ONC by Market Capitalization
Companies near Oncolytics Biotech Inc in the global market cap rankings as of September 19, 2026. Review ONC goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Oncolytics Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Oncolytics Biotech Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Oncolytics Biotech Inc's market cap moved from $265.53 Million to $ 1.08 Billion, with a yearly change of 10.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | CA$1.08 Billion | +1020.30% |
| 2024 | CA$96.56 Million | -25.70% |
| 2023 | CA$129.95 Million | -19.37% |
| 2022 | CA$161.17 Million | +26.86% |
| 2021 | CA$127.05 Million | -42.05% |
| 2020 | CA$219.25 Million | -50.89% |
| 2019 | CA$446.49 Million | +145.02% |
| 2018 | CA$182.23 Million | -62.79% |
| 2017 | CA$489.68 Million | +167.92% |
| 2016 | CA$182.77 Million | -31.17% |
| 2015 | CA$265.53 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 2nd, 2026 the market cap of Oncolytics Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $142.51 Million USD |
| MoneyControl | $142.51 Million USD |
| MarketWatch | $142.51 Million USD |
| marketcap.company | $142.51 Million USD |
| Reuters | $142.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more